Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.